Edition:
United States

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

10.08USD
17 Nov 2017
Change (% chg)

$-0.05 (-0.49%)
Prev Close
$10.13
Open
$10.04
Day's High
$10.13
Day's Low
$9.86
Volume
94,801
Avg. Vol
103,486
52-wk High
$22.46
52-wk Low
$8.30

Chart for

About

Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. The Company's... (more)

Overall

Beta: 1.39
Market Cap(Mil.): $308.86
Shares Outstanding(Mil.): 30.64
Dividend: 0.06
Yield (%): 2.58

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Aceto reports fiscal 2018 first quarter results

* Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S

Nov 02 2017

BRIEF-Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​

* Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​ Source text : ( http://bit.ly/2yQZ0rq ) Further company coverage:

Oct 27 2017

BRIEF-ACETO SAYS UNIT, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML Source text for Eikon: Further company coverage:

Oct 24 2017

BRIEF-ACETO appoints William Kennally, III president and CEO

* ACETO Corp - ‍Salvatore Guccione, ACETO's chief executive officer has stepped down from all positions with ACETO​ Source text for Eikon: Further company coverage:

Sep 27 2017

BRIEF-Aceto Q4 EPS $0.06

* Aceto reports fiscal 2017 fourth quarter and full year results

Aug 24 2017

Earnings vs. Estimates